



[ATW] CELLfinity – Hybrid in vivo CGT
for scalable patient access

February 2026

A microscopic view of numerous cells, likely cancer cells, with a blue and teal color palette. The cells are of various sizes and are scattered across the frame, some in sharp focus and others blurred in the background. The overall tone is scientific and clinical.

**DELIVERING
UNPRECEDENTED SAFE *IN
VIVO* CELL THERAPIES
THROUGH PRECISION
TARGETING**

MAKING CHALLENGING DISEASES CURABLE - FOR

TQx OFFERS THE ONLY SAFE *IN VIVO* CELL & GENE THERAPY TO PATIENTS IN NEED ACROSS INDICATIONS AT LOW COST



Trinity:

TQx's unique *in vivo* **process** leverages a safety step via our **delivery application**, creating safe & scalable **therapies**



Unique “TQ hybrid in vivo approach”
– an in-vivo therapy with a safety step

***In vivo* drug delivery application**
powered by our clinical process platform CELLfinity

First clinical trial in 2027 aiming to launch own *in vivo* cell therapy to market




TQx's CELLbricator DRUG DELIVERY SYSTEM ENABLES SAFE IN VIVO THERAPY APPLICATION

TQx Drug Delivery System

DRUG DELIVERY SYSTEM

Controlled in-vivo drug delivery at the patients' bed side



HYBRID IN VIVO APPROACH





T-CELLS ARE SELECTED AND GENETICALLY MODIFIED, CAR EXPRESSES IN VIVO, T-CELL SELECTIVITY DRIVES SAFETY

„TQx Hybrid in vivo“ Approach

SAFETY & PRECISION – LEAP FROGGING AUTOLOGOUS mRNA-T-CELL THERAPEUTICS

„TQx HYBRID IN VIVO“ APPROACH


1. EX VIVO - Drug Delivery System

T-cell selection & automated extracorporeal transient modification of autologous donor T-cells (no CARs expressed)



2. IN VIVO - In Patient

In vivo generation and activity of transiently CAR expressing T cells





BOTH EX VIVO AND IN VIVO MODALITIES HAVE DIFFERENT CONTROL PROFILES AND WILL SERVE DIFFERENT INDICATIONS

Ex Vivo MMF vs. In Vivo CAR-T



OUR MODULAR CELLfinity PLATFORM UNLOCKS INFINITE CGT CLINICAL PROGRAM POSSIBILITIES FOR PHARMA



TQx CELLfinity Platform

CELLfinity PLATFORM	INDICATION	SELECTION MARKER	TRANSFECTION METHOD	INTEGRATION	TARGET / RECEPTOR
PIPELINE PROGRAM 01	Haemato-Oncology	T-Cells CD 3+	Viral Vectors	Transient	CD 19 CAR
PIPELINE PROGRAM 02	Autoimmune				BCMA CAR
PIPELINE PROGRAM 03	Infectious disease	B-Cells CD 19	LNPs	Stable	CD 22 CAR
PIPELINE PROGRAM 04	Neurology		Electroporation		TCR
PIPELINE PROGRAM 05	Solid tumors	NK Cells CD 56		Hybrid	CAAR
	Orphan disease		Mechanoporation		

OUR TEAM CONSISTS OF EXPERTS WITH COMPLEMENTARY SKILLS



Dr. Christian Eckert
Co-Founder & CEO



Dr. Christian Stemberger
Co-Founder & CSO



Sabine Radisch
Co-Founder & CTO



Dr. Stefan Dreher
Co-Founder & COO



Christin Zündorf
Chief Business Officer



INVESTORS & FUNDING



Bristol Myers Squibb™

HTGF

FRESENIUS KABI

SPRIN-D easygen

ADVISORS



Prof. Mougikakos
University
Magdeburg



Prof. Krönke
Rheumatology
Charité Berlin



Dr. med. A. Schmidts
PI at TU Munich



Tim Campbell
VP Early Clinical
Dev. CGT @BMS



Lorenz Mayr, Ph.D.
Ex-Biopharma
Executive



FUNDRAISING OPPORTUNITY: RAISING \$30 MIO SERIES A



Christin Zündorf

Chief Business Officer

c.zuendorf@tqtherapeutics.com



VISIT US AT BOOTH #623
OR LET'S STAY
CONNECTED.